Triplixam 10mg/2.5mg/5mg 2p x 30 tablets — Made in Ireland — Free Delivery

Pharmachologic effect

Indication for use

Contraindications

• angioedema (Quincke's edema) while taking ACE inhibitors in history
• hereditary / idiopathic angioedema;
• severe renal failure (CC less than 30 ml / min);
• moderate renal failure (CC less than 60 ml / min) for the dosage of the combination of perindopril / indapamide 10 mg / 2.5 mg (i.e. Triplixam® 5 mg + 2.5 mg + 10 mg and Triplixam® 10 mg + 2.5 mg + 10 mg) ;
• patients on hemodialysis;
• bilateral stenosis of the renal arteries, stenosis of the artery of a single kidney;
• severe liver failure;
• hepatic encephalopathy;
• hypokalemia;
• severe arterial hypotension (systolic blood pressure less than 90 mm Hg);
• shock (including cardiogenic);
• untreated heart failure in the stage of decompensation;
• hemodynamically unstable heart failure after acute myocardial infarction;
• obstruction of the left ventricular outflow tract (eg, clinically significant aortic stenosis);
• simultaneous use with aliskiren-containing preparations in patients with diabetes mellitus or impaired renal function (GFR <60 ml / min / 1.73 m2 of body surface area)
• simultaneous use with preparations that can cause polymorphic ventricular tachycardia of the "pirouette" type;
• simultaneous use with preparations that prolong the QT interval;
• simultaneous use with potassium-sparing diuretics, potassium and lithium preparations, in patients with an increased content of potassium in the blood plasma;
• pregnancy
• breastfeeding period
• age up to 18 years (efficacy and safety have not been established);
• hypersensitivity to the active and auxiliary substances that make up the preparation, sulfonamide derivatives, dihydropyridine derivatives, other ACE inhibitors, any other substances that make up the preparation.

Storage conditions